tiprankstipranks
Invion Limited Reports Promising Cancer Trial Results
Company Announcements

Invion Limited Reports Promising Cancer Trial Results

Invion Ltd. (AU:IVX) has released an update.

Don't Miss our Black Friday Offers:

Invion Limited has reported promising results from its Phase II prostate cancer trial, showing that their lead drug candidate, INV043, is safe, well tolerated, and effective in reducing lesion size. With 44% of patients showing negative PSMA-PET results post-treatment, the company is optimistic about further exploring INV043’s potential in a new skin cancer trial. Invion’s strategic presentations at international biotech conferences highlight the growing interest in their innovative Photosoft technology.

For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskInvion Limited’s Annual Meeting Boosts Investor Confidence
TipRanks Australian Auto-Generated NewsdeskInvion Ltd. Advances in Cancer Therapy Innovations
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App